Dr. Mary Feng, MD
Claim this profileUniversity of California, San Francisco
Studies Skin Cancer
Studies Hepatocellular Carcinoma
2 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Mary Feng, MD is currently running
Radiation Therapy
for Gastrointestinal Cancer
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
Recruiting1 award N/A14 criteria
Radiotherapy + Immunotherapy
for Liver Cancer
This phase II trial studies how well standard of care hypofractionated radiation therapy followed by durvalumab with or without tremelimumab works in treating patients with hepatocellular cancer (liver cancer) that has spread to other places in the body (advanced) and that is growing, spreading, or getting worse (progressing) after treatment with PD-1 inhibitor immunotherapy. In some patients, cancer cells and immune cells start to express signals that stop the body's immune system from killing the cancer. New drugs being developed, such as durvalumab and tremelimumab, are designed to target and block these signals and may help increase the immune response to prevent or slow down cancer growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may help the immune system work even better. Giving durvalumab with or without tremelimumab after radiation therapy may work better than radiation therapy alone in treating patients with liver cancer.
Recruiting1 award Phase 2
More about Mary Feng, MD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mary Feng, MD has experience with
- Radiation Therapy
- Durvalumab
- Hypofractionated Radiation Therapy
- Tremelimumab
Breakdown of trials Mary Feng, MD has run
Skin Cancer
Hepatocellular Carcinoma
Liver Cancer
Colorectal Cancer
Gastric Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary Feng, MD specialize in?
Mary Feng, MD focuses on Skin Cancer and Hepatocellular Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Mary Feng, MD currently recruiting for clinical trials?
Yes, Mary Feng, MD is currently recruiting for 2 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Mary Feng, MD has studied deeply?
Yes, Mary Feng, MD has studied treatments such as Radiation Therapy, Durvalumab, Hypofractionated Radiation Therapy.
What is the best way to schedule an appointment with Mary Feng, MD?
Apply for one of the trials that Mary Feng, MD is conducting.
What is the office address of Mary Feng, MD?
The office of Mary Feng, MD is located at: University of California, San Francisco, San Francisco, California 94143 United States. This is the address for their practice at the University of California, San Francisco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.